Xentria Announces New Key Appointments to its TeamRead more
Early data presented support the evaluation of XTMAB-16 as a potential therapy for patients with sarcoidosisRead more
Findings Demonstrating Suppression of the Inflammatory Pathways Promoting Sarcoidosis Granuloma Formation to be Highlighted in Poster PresentationRead more
Episode to be Rebroadcast on December 14th, 2021 at 7:30 a.m. (ET/PT)Read more
Xentria Announces the Initiation of a Clinical Trial for XTMAB-16 for the Treatment of SarcoidosisRead more
NKF and Meitheal Announce Dr. Jiali Luo as General Manager of New Biopharmaceutical BusinessRead more
Important Regulatory Milestone Provides Runaway to Move XTMAB-16 into the Clinical PhaseRead more
Xentria Announces FDA Orphan Drug Designation for XTMAB-16 in SarcoidosisRead more
Unveiling Possibilities brings connection, expertise, and shared experiences to help patients and loved ones throughout the sarcoidosis journey. FSR's Patient Summit is a two-day online opportunity for learning, community, and wellness.
Xentria presents new data on XTMAB-16 with a poster presentation at the American Thoracic Society (ATS) International Conference 2022 in San Francisco, CA.
Behind the Mystery is a special segment dedicated to revolutionizing the way the health care system works for those suffering from a rare and genetic disorder. Segments highlight the emotional, scientific, and medical aspects associated with rare and genetic diseases. The goal is to expand awareness for rare and genetic diseases through partnerships with pharmaceutical and biotech companies, while giving voices to the patients, families, and advocates affected via our national television platform. December’s specialized segment will focus on sarcoidosis, a rare inflammatory disease that can affect almost any organ in the body.
Topics will focus on interstitial lung diseases (ILD) including sarcoidosis along with cutting-edge advances in parenchymal lung disease and cardiac sarcoidosis.
Join an interdisciplinary audience of practitioners and healthcare professionals who seek to learn the latest developments in sarcoidosis and interstitial lung disease. Learn more about this meeting at their website.
On Wednesday, October 20th, the EveryLife Foundation’s 13th Annual Rare Disease Scientific Workshop explores the “Current and Future Barriers to the Utilization of Accelerated Approval Pathway for Novel Rare Disease Therapies.” Through expert panels and real-world case study presentations, partners representing patient advocates, government agencies, pharmaceutical companies, and researchers identify the research, regulatory, and access policy barriers to increasing the utilization of the Accelerated Approval pathway for rare disease therapeutic development. Watch the event Livestream, HERE, on October 20th, and join the conversation on social media using #ScientificWorkshop2021.
FSR is hosting their inaugural Clinical Engagement Conference which brings together members of the healthcare community for an opportunity to unite and discuss ways to best serve the sarcoidosis community.
The Foundation for Sarcoidosis Research (FSR) is the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and to improving care for sarcoidosis patients. Since its establishment in 2000, FSR has fostered over $5 million in sarcoidosis-specific research efforts and has worked diligently to provide resources to thousands.
FSR’s Virtual Summit is a two-day online opportunity for learning, community, and wellness. These events allow patients living with sarcoidosis to connect with leading experts in both the clinical and research fields.
Involving patients and collaborating with the community are the fundamental basics of patient-centered drug development. Xentria held a Patient Focus Group aimed to better understand the real-life needs of people who live with sarcoidosis by involving the patient experience and perspective.